Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
EBR Systems Inc (ASX:EBR)
ALERT: Price-sensitive ASX Announcement for EBR
Current share price for EBR : $0.385 -0.6 (-60.91%)+
Announcement
Release
12 Jan 2026 8:30AM
Price at Release
$0.985
Full Release
Summary
EBR Systems, Inc. reported strong commercial and clinical progress in Q4 FY2025. The company saw a doubling of case volumes from Q3 2025 with 18 successful WiSE System implants, reaching a total of 30 implants. Revenue for Q4 2025 is expected to be between US$870K and US$935K, while total revenue for 2025 is projected to be between US$1,552K and US$1,617K, pending final adjustments. The company advanced its WiSE-UP post-approval study and initiated the TLC-AU feasibility study. EBR's commercial adoption continued with 9 additional purchase agreements and 11 new physicians trained. The company's efforts were underscored by active participation in investor conferences and media engagements.
Key Points
- Strong commercial momentum in Q4 2025.
- Doubling of case volumes with WiSE System implants.
- Expected revenue range for Q4 2025 is US$870K to US$935K.
- Total revenue for 2025 projected to be US$1,552K to US$1,617K.
- Commencement of the WiSE-UP post-approval study.
- Initiation of the TLC-AU feasibility study.
- 9 additional purchase agreements signed.
- 11 new physicians trained for WiSE System implantation.
- Active investor engagement and participation in conferences.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
